A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer: Sequential phase I/II studies

Bone Marrow Transplantation

Volumn 28, Issue 5, 2001, Pages 447-454

  Elias, A D ^a   Richardson, P ^a   Avigan, D ^a   Ibrahim, J ^a   Joyce, R ^a   McDermott, D ^a   Levine, J ^a   Warren, D ^a   McCauley, M ^a   Wheeler, C ^a   Frei III, E ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Double transplant; Hematopoietic stem cell support; Metastatic breast cancer

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIPHENHYDRAMINE; DOXORUBICIN; GLUTATHIONE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; MESNA; PACLITAXEL; PHOSPHORUS DERIVATIVE; RANITIDINE; THIOTEPA; TRASTUZUMAB; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID;

ADULT; ADVANCED CANCER; ARTICLE; BOLUS INJECTION; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS RESISTANCE; DEATH; DRUG INFUSION; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; DRUG TOXICITY; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN TISSUE; LEUKAPHERESIS; MOBILIZATION; NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SAFETY; STANDARD; STATISTICAL ANALYSIS; SURVIVAL;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MELPHALAN; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL; REMISSION INDUCTION; SURVIVAL RATE; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0035175185     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703148     Document Type: Article

References (25)

1. Phase III trial of doxorubicin versus paclitaxel versus doxorubicin plus paclitaxel as first-line therapy for metastatic breast cancer: An intergroup trial
2. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America
3. Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem cell support for advanced breast cancer
4. A preclinical model for sequential high dose chemotherapy
5. A phase I trial of double transplant for metastatic breast cancer: Sequence and interval considerations
6. Tandem high-dose chemotherapy with stem cell rescue (HD-SCR) in patients with breast cancer - Effect of sequence
7. The interval between courses of high-dose chemotherapy with stem cell rescue: Therapeutic hypotheses
8. Characteristics of five human tumor cell lines and sublines resistant to cis-diamminedichloroplatinum (II)
9. Antitumor alkylating agents: In vitro cross-resistance and collateral sensitivity studies
10. A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer
11. Kinetics of peripheral blood mononuclear cell mobilization with chemotherapy and/or granulocyte-colony stimulating factor (G-CSF): Implications for timing and yield of hematopoietic progenitor cell collections
12. Glutamine preserves liver glutathione after lethal hepatic injury
13. Ursodiol to prevent hepatic venoocclusive disease
14. Planning the size and duration of a clinical trial studying the time to some critical event
15. A multiple testing procedure for clinical trials
16. Nonparametric estimation from incomplete observation
17. Paclitaxel-induced neuropathy
18. Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer
19. Patient selection in high-dose chemotherapy trials: Relevance in high-risk breast cancer
20. Conventional- vs high-dose therapy for metastatic breast cancer: Comparison of Cancer and Leukemia Group B (CALGB) and Blood and Marrow Transplant Registry (ABMTR) patients
21. A phase II study of high dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard dose therapy
22. High dose chemotherapy with hematopoietic stem cell transplantation for metastatic breast cancer: Results of the French protocol PEGASE 04
23. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer
24. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: A randomized trial